Neurofilament light is a treatment‐responsive biomarker in CLN2 disease

NFL is a marker of treatment response in children with SMA treated with nusinersen

(2019) Bob Olsson et al.   JOURNAL OF NEUROLOGY

Neurofilament light protein in blood predicts regional atrophy in Huntington disease

(2018) Eileanoir B. Johnson et al.   NEUROLOGY

Study of Intraventricular Cerliponase Alfa for CLN2 Disease

(2018) Angela Schulz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease)

(2018) Miriam Sindelar et al.   Scientific Reports

Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression

(2017) M L Katz et al.   GENE THERAPY

Proteomic Analysis of Brain and Cerebrospinal Fluid from the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Potential Biomarkers

(2017) David E. Sleat et al.   JOURNAL OF PROTEOME RESEARCH

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

(2017) Lauren M Byrne et al.   LANCET NEUROLOGY

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP

(2017) Julio C. Rojas et al.   NEUROLOGY

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models

(2017) Amalie Clement et al.   NEUROSCIENCE

Management Strategies for CLN2 Disease

(2017) Ruth E. Williams et al.   PEDIATRIC NEUROLOGY

Pharmacokinetic aspects of retinal drug delivery

(2017) Eva M. del Amo et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

Pharmacodynamic effects of daclizumab in the intrathecal compartment

(2017) Mika Komori et al.   Annals of Clinical and Translational Neurology

Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum

(2016) Carlo Wilke et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

(2016) Jonathan D. Rohrer et al.   NEUROLOGY

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

(2016) Mehtap Bacioglu et al.   NEURON

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

(2016) Henrik Zetterberg et al.   JAMA Neurology

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Neurofilament light chain: a biomarker for genetic frontotemporal dementia

(2016) Lieke H. Meeter et al.   Annals of Clinical and Translational Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury

(2016) Pashtun Shahim et al.   Scientific Reports

Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis

(2015) Patrick Weydt et al.   ANNALS OF NEUROLOGY

Bridging NCL research gaps

(2015) Frank Stehr et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis

(2015) C.-H. Lu et al.   NEUROLOGY

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)

(2014) Martin L. Katz et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease

(2014) Kelly A. Meulendyke et al.   JOURNAL OF NEUROVIROLOGY

The neuronal ceroid-lipofuscinoses

(2013) Michael J. Bennett et al.   Developmental Disabilities Research Reviews

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

Assessment of Disease Severity in Late Infantile Neuronal Ceroid Lipofuscinosis Using Multiparametric MR Imaging

(2012) J.P. Dyke et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

The neuronal ceroid-lipofuscinoses: A historical introduction

(2012) Matti Haltia et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis

(2011) D. N. Sanders et al.   GENES BRAIN AND BEHAVIOR

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY